Suppr超能文献

"Pleurex 脱盐" 在恶性肿瘤相关腹水:低钠血症的新机制。

"Pleurex Desalination" in Malignancy-related Ascites: A Novel Mechanism of Hyponatremia.

机构信息

Department of Medicine, Division of Renal Medicine, Brigham and Women's Hospital.

Dana-Farber Cancer Institute.

出版信息

Am J Clin Oncol. 2020 Jan;43(1):14-19. doi: 10.1097/COC.0000000000000618.

Abstract

OBJECTIVE

Pleurex catheters are a form of palliative therapy for patients, offering relief from symptomatic ascites while also affording greater independence and flexibility; however, aggressive drainage can lead to significant total body sodium losses. We describe the course of patients with "Pleurex desalination," an under-appreciated cause of hypovolemic hyponatremia, highlighting its unique pathophysiology and providing recommendations on how to manage these complex patients.

PATIENTS AND METHODS

We included representative patients with "Pleurex desalination" who were evaluated and treated by the renal consult service at Brigham and Women's between 2017 and 2019.

RESULTS

We identified 3 patients who were hospitalized with "Pleurex desalination" and had complete data on serum and urine studies, as well as treatment course. We demonstrate that patients with "Pleurex desalination" were removing up to 1 to 2 L of ascitic fluid a day and were admitted with signs and symptoms of profound hypovolemia and hyponatremia. Patients worsened with administration of diuretics and salt restriction and improved with aggressive fluid resuscitation in the form of hypertonic saline, normal saline, and/or intravenous albumin.

CONCLUSION

"Pleurex desalination" is an under-recognized cause of hyponatremia; at-risk patients require close observation and periodic resuscitation with intravenous, volume-expanding fluids.

摘要

目的

引流导管是一种姑息疗法,可为有症状的腹水患者提供缓解,并提供更大的独立性和灵活性;然而,过度引流会导致大量的总钠丢失。我们描述了“引流导管脱盐”患者的病程,这是低容量性低钠血症的一个未被充分认识的原因,强调了其独特的病理生理学,并就如何管理这些复杂的患者提供了建议。

患者和方法

我们纳入了 2017 年至 2019 年期间在布里格姆妇女医院接受肾脏咨询服务评估和治疗的“引流导管脱盐”代表性患者。

结果

我们确定了 3 名患有“引流导管脱盐”并具有完整血清和尿液研究以及治疗过程数据的住院患者。我们证明,“引流导管脱盐”患者每天可去除多达 1 至 2 升的腹水,并因严重低血容量和低钠血症的症状和体征而入院。患者在给予利尿剂和盐限制后病情恶化,并通过高渗盐水、生理盐水和/或静脉白蛋白进行积极的液体复苏而改善。

结论

“引流导管脱盐”是低钠血症的一个未被充分认识的原因;高危患者需要密切观察,并定期通过静脉补液进行复苏。

相似文献

1
"Pleurex Desalination" in Malignancy-related Ascites: A Novel Mechanism of Hyponatremia.
Am J Clin Oncol. 2020 Jan;43(1):14-19. doi: 10.1097/COC.0000000000000618.
2
Incidence of Hyponatremia in Patients With Indwelling Peritoneal Catheters for Drainage of Malignant Ascites.
JAMA Netw Open. 2020 Oct 1;3(10):e2017859. doi: 10.1001/jamanetworkopen.2020.17859.
4
Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
Intern Med. 2018 Sep 1;57(17):2451-2458. doi: 10.2169/internalmedicine.0629-17. Epub 2018 Mar 30.
5
[Hyponatremia in liver cirrhosis: pathogenesis and treatment].
Endocrinol Nutr. 2010 May;57 Suppl 2:15-21. doi: 10.1016/S1575-0922(10)70018-8.
6
[Treatment of ascites, hyponatremia and hepatorenal syndrome in liver cirrhosis].
Ther Umsch. 2009 Nov;66(11):747-51. doi: 10.1024/0040-5930.66.11.747.
8
Approach and management of dysnatremias in cirrhosis.
Hepatol Int. 2018 Nov;12(6):487-499. doi: 10.1007/s12072-018-9894-6. Epub 2018 Sep 10.
9
Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination.
Ann Intern Med. 1997 Jan 1;126(1):20-5. doi: 10.7326/0003-4819-126-1-199701010-00003.
10
Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
BMC Gastroenterol. 2018 Sep 4;18(1):137. doi: 10.1186/s12876-018-0857-0.

引用本文的文献

1
Daily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites.
JAMA Netw Open. 2023 Jul 3;6(7):e2322048. doi: 10.1001/jamanetworkopen.2023.22048.
2
Incidence of Hyponatremia in Patients With Indwelling Peritoneal Catheters for Drainage of Malignant Ascites.
JAMA Netw Open. 2020 Oct 1;3(10):e2017859. doi: 10.1001/jamanetworkopen.2020.17859.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验